The Weizmann Institute establishes the Nancy and Stephen Grand Israel National Center for Personalized Medicine
A new national center has been established at the Weizmann Institute of Science designed to provide Israeli science and industry with much-needed state-of-the-art research platforms in the cutting-edge biomedical fields of genomics, protein profiling, bioinformatics, and drug discovery. The Center will leverage advances in each of these areas to make more personalized medicine a reality.
The concept of a centralized service facility that caters to the entire biomedical research community is a novelty in Israel. This fall, Nancy and Stephen Grand of San Francisco gave a visionary gift towards the new center that bears their name, the Nancy and Stephen Grand Israel National Center for Personalized Medicine. The Center includes four pillars: the Crown Institute for Genomics, the de Botton Institute for Protein Profiling, the Ilana and Pascal Mantoux Institute for Bioinformatics and the Maurice and Vivienne Wohl Institute for Drug Discovery.
The complete sequencing of the human genome combined with a string of major technological developments marked a major turning point in biomedical research. This shift is highlighted by the stellar rise of the fields of genomics, protein profiling, and bioinformatics. Another advancement is small-molecule high-throughput screening, colloquially referred to as “drug discovery,” where researchers search for molecules that block or correct the activities of suspected noxious factors, often resulting in potential lead compounds for new drugs.
These are all costly research platforms that have become essentially mandatory for biomedical exploration. Unifying these platforms under one roof will enable efficiency in research undertakings, as well as cross-talk among scientists, industry, and hospitals—all for the benefit of biomedical knowledge and patient health.